Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States

American Journal of Hematology

Volumn 66, Issue 4, 2001, Pages 229-240

  Chorba, Terence L ^a,c   Holman, Robert C ^a   Clarke, Matthew J ^b   Evatt, Bruce L ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; Hemophilia; HIV; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CHILD; HEMOPHILIA A; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MORTALITY; NEWBORN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CONTINENTAL POPULATION GROUPS; DEATH CERTIFICATES; DIAGNOSIS-RELATED GROUPS; FEMALE; HEMOPHILIA A; HEMORRHAGE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; RESPIRATION DISORDERS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; UNITED STATES;

EID: 0035098164     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.1050     Document Type: Article

References (71)

1. Deaths in Swedish hemophiliacs, 1957-80
2. Pilot Study of Hemophilia Treatment in the United States. National Blood Resource Program
3. Haemophilia
4. Occurrence of hemophilia in the United States
5. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate
6. Hemophilia: Yesterday, today and tomorrow
7. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States
8. Recent changes in longevity and causes of death among persons with hemophilia A
9. The benefits of comprehensive care for hemophilia: A five-year study of outcomes
10. Pneumocystis carinii pneumonia among persons with hemophilia A
11. Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody: Association with hemophiliacs' immune status and blood component usage
12. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study
13. TRANSAX, the NCHS system for producing multiple cause-of-death statistics, 1968-78
14. Analytical potential for multiple cause-of-death data
15. Impact of HIV infection on mortality and accuracy of AIDS reporting on death certificates
16. HIV-related deaths from selccted infectious diseases among persons without AIDS in New Jersey
17. The effect of physician terminology preference on coronary heart disease mortality: An artifact uncovered by the 9th revision ICD
18. Prevention Update trends in AIDS incidence - United States, 1996
19. Births and deaths: Preliminary data for 1997
20. Accuracy of death certificate completion: The need for formalized physician training
21. Unrecognized HIV-related deaths
22. Trends in infectious diseases mortality in the United States
23. Human immunodeficiency virus infection due to clotting factor concentrates: Results of the Seroconverion Surveillance Project
24. Cause of death in hemophilia A patients in the United States from 1968 to 1979
25. Mortality among males with hemophilia: Relations with source of medical care
26. Population projections of the United States, by age, sex, race and Hispanic origin: 1993 to 2050
27. Factor VIII inhibitors
28. Postpartum acquired factor VIII inhibitors: Results of a survey
29. Effect of age at seroconversion on the natural AIDS incubation distribution
30. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
31. Risk factors for infection with hepatitis B and hepatitis C viruses in a large cohort of hemophilic males
32. Natural history of human immunodeficiency virus infection in hemophiliacs: Effects of T-cell subsets, platelet counts, and age
33. Age and human immunodeficiency virus infection in persons with hemophilia in California
34. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia
35. Censoring in an epidemic with an application to hemophilia-associated AIDS
36. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study
37. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population
38. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active anti-retroviral therapy: A collaborative re-analysis
39. Progressive liver disease in haemophilia: An understated problem
40. Causes of death in hemophilia
41. Hepatitis B virus, hepatitis A virus and persistently elevated aminotransferases in hemophiliacs
42. The prevalence of antibody to hepatitis C in a cohort of hemophilic patients
43. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A non-B hepatitis
44. Posttransfusion non-A, non-B hepatitis: Physicochemical properties of two distinct agents
45. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
46. Increasing hepatitis C vires RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease
47. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
48. The epidemiology of HIV and AIDS in the United States
49. Prevention Surveillance for AIDS-defining opportunistic illnesses
50. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients
51. The effects on survival of early treatment of human immunodeficiency virus infection
52. Effect of comprehensive intervention program on survival of patients with human immunodeficiency virus infection
53. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients
54. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors
55. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
56. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
57. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity
58. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease
59. Antiretroviral therapy: Where are we?
60. National HIV case reporting for the United States
61. Decay characteristics of HIV-1 infected compartments during combination therapy
62. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection